

Ref no: 012090620
From: Public
Date: 09/06/20
Subject: Prescribing in Growth Hormone

REQUEST

I have a Freedom of Information request. Could you please answer the questions below?

1. In your Trust how many patients have been treated with the following Somatostatin Analogues in the latest 12-month period for which data are available?

- Octreotide
- Lanreotide
- Pasireotide

2. In the latest 12-month period how many Acromegaly patients have been treated with the following drugs?

- Sandostatin LAR
- Octreotide Long-Acting (Generic)
- Somatuline Autogel
- Pasireotide
- Pegvisomant

3. How many patients have received a somatropin treatment for growth hormone deficiency in the latest 12-month period?

- Genotropin
- Humatrope
- Norditropin
- Nutropin
- Omnitrope
- Saizen
- Zomacton

4. If it is possible, can you provide the number of patients under the age 16 that were treated with each of the following drugs in the latest 12-month period?

- Genotropin
- Humatrope
- Norditropin
- Nutropin

- Omnitrope
- Saizen
- Zomacton

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust does not hold the information that you have requested. Section 17 of Freedom of Information Act states that where public authorities receive requests for information that they do not hold, they must issue a notice advising that they do not hold the requested information.

Of the drugs listed in your request we are able to tell you which have been dispensed and to how many patients have received the drugs, but not what they were treated for. Please see the table below for this information which shows the number of patients who have been issued with the selected drug during the period 1st June 2019 to 1st June 2020 for any indication:

* **Please note:** We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.

Drug	Pack	Patients
OCTREOTIDE [:AMPOULE] 500 micrograms/1ml Injection	5 x 1mL ampoule Pack	*<5
OCTREOTIDE [:VIAL] 500 micrograms/1ml Injection	5 x 1mL vial Pack	*<5
OCTREOTIDE 1 mg/5ml Injection	1 vial Pack	19
OCTREOTIDE 100 micrograms/1ml Injection	5 x 1mL ampoule Pack	12
OCTREOTIDE 100 micrograms/1ml Pre-filled syringe	5 x 1mL Prefilled Syringe Pack	*<5
OCTREOTIDE 50 micrograms/1ml Injection	5 x 1mL ampoule Pack	7
OCTREOTIDE 500 micrograms/1ml Pre-filled syringe	5 x 1mL Prefilled Syringe Pack	7
OCTREOTIDE 'SANDOSTATIN LAR' 30 mg Injection	1 Vial Pack	*<5
SOMATROPIN 'GENOTROPIN MINIQUICK' 0.2 mg Pre-filled disposable device	7 x prefilled syringe Pack	*<5
SOMATROPIN 'GENOTROPIN MINIQUICK' 0.4 mg Pre-filled disposable device	7 x prefilled syringe Pack	*<5
SOMATROPIN 'GENOTROPIN MINIQUICK' 0.6 mg Pre-filled disposable device	7 x prefilled syringe Pack	*<5
SOMATROPIN 'NORDITROPIN SIMPLE Xx' 10 mg/1.5ml Cartridge	1 cartridge Pack	*<5
SOMATROPIN 'NUTROPIN AQ' 10 mg Cartridge	1 x 2mL cartridge Pack	*<5